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Significance of the problem
Abdominal aortic aneurysms (AAA) are found in 6%
(95% confidence interval [CI] 5-6) of men over the age of
641-4 and 1% (95% CI 1-2) of women in the same age
group.5 AAAs confer a risk of spontaneous rupture and
death, which is related to the diameter of the aneurysm: a
risk of rupture of 0.5%, 1%, 11%, and 26% per year has been
associated with a diameter of 4 cm, 4.0 to 4.9 cm, 5.0 to
5.9 cm, 6.0 to 6.9 cm, respectively.6-8 Population based
studies show that 66% (95% CI 58-73) of patients with
ruptured aneurysms die before reaching the hospital or in
the hospital before operative repair.9 For those who un-
dergo surgery, the operative mortality for ruptured AAAs is
reported to be 41% (95% CI 40-42) in a recent large
observational study10 and 48% (95% CI 46-50) in a meta-
analysis of cohort studies.11 The 30-day perioperative mor-
tality for elective open repair of AAAs is reported in most
series and randomized controlled trial it is 5% to 8%.12-24
The screening tool
Ultrasonography has the characteristics of the ideal
screening tool (simplicity, safety, reliability, validity, cost
effectiveness and acceptance to the public25) and has been
used in previous RCTs of screening programs.1-4 It is able
to define the diameter of the infrarenal aorta in 98% (95%
CI 92-94) of individuals,26 with a sensitivity and specificity
of 100% and 98%, respectively.27 The correlation between
observers for ultrasound measurements of the abdominal
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1268aorta is high (Spearman coefficient 0.99), but abdominal
girth reduces the precision of the measurement.28
A focused physical examination has been investigated as
a screening tool to identify AAA. Sensitivity has been
reported in the range of 76% to 85% and specificity 85% for
AAA 5 cm 29,30 with moderate interobserver agreement
(kappa  0.5).31 The diagnostic properties of physical
examination require further investigation.
The evidence for screening
Outcome mortality. Several large population based
studies32-38 and four RCTs of men over 65 years old1-5
investigated the effect of screening programs on AAA re-
lated mortality. The pooled estimate of the effect of screen-
ing based on the meta-analysis of four RCTs showed a
relative risk (RR) of 0.60 (95%CI 0.45-0.80; P .0004) in
favor of screening men 65 years of age (Fig 1).39 The
absolute risk reduction (ARR) for the outcome mortality
was 0.13% (95% CI 0.07-0.21), which corresponds to a
number needed to screen (NNS) of 769 (95% CI 476-
1428) over 3.4 years. If only trials that screened patients 65
to 75 years old are considered, the ARR reduction for the
outcome mortality was 0.16% (95% CI 0.13-0.2), which
corresponds to a number needed to screen (NNS) of 625
(95%CI 500-769) over 4 years. The details of the screening
protocols used in these RCTs are presented in Table I
(online only).1-4
Rescreening. Two of the RCTs looked at the need for
rescreening in individuals with 3 cm AAA: the Viborg
trial1 repeated an ultrasound examination (USE) 3 to 5
years after the first one and found that new AAA  3 cm
occurred in 28% (95% CI 21-35), but none were clinically
significant (the largest 48 mm)1; and the Chichester trial
rescreened patients with aortic diameter 3 cm every 2
years and identified 4.1% AAA, which were all 3.8 cm in
diameter.40
Age. Age affects themagnitude of benefit from screen-
ing. Males over the age of 75 were included in two of the
four RCTs3,4; and the pooled RR for mortality was 0.76
aneu
rtic a
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excluded older men a larger benefit was identified (RR
0.49; 95% CI 0.3-0.8, P  .005) (Fig 2). The reduced
benefit of screening elderly males is due to the reduced life
expectancy and to the demonstrated increased mortality
after AAA repair (odds ratio [OR] 2.11; 95% CI 1.03-4.32,
for each 10-year increase in age).41
Women. One of the RCTs5 included 9342 women.
The prevalence of AAA3 cm was 1% (95% CI 1-2) and of
AAA5 cm was 0.1% (95% CI 0.3-2.3); screening did not
reduce mortality (RR  1.49, 95% CI 0.72-3.10).5
Data from the ADAM screening program shows that
female sex is a negative risk factor for the presence of AAA
(OR 0.17, 95% CI 0.07-0.48).42 In this study, the stron-
gest risk factor associated with AAA was a smoking history:
the prevalence of AAA3 cm was 0.4% (95% CI 0.08-0.7)
in nonsmokers and 1.5% (95% CI 1-2) in women who ever
Fig 1. Pooled relative risk abdominal aortic
Fig 2. Pooled relative risk of abdominal aosmoked.42 This corresponds to a four-fold greater risk insmokers than nonsmokers (OR 3.8, 95% CI 1.57-9.20). In
women with aneurysms, however, other risk factors were
similar to men. Of these, the presence of cerebrovascular
disease (OR 3.20, 95% CI 1.48-6.92), family history of
AAA (OR 2.6 95% CI 1.1-6.0) and age (OR 1.8, 95% CI
1.2-2.6) were statistically significant, while coronary artery
disease was not (OR 1.38, 95% CI 0.68-2.81).42 Given the
low (0.1%) baseline prevalence of clinically significant (4
cm) AAA in women, from a population based perspective,
even in women smokers the prevalence of AAA is still very
low (0.4%, 95% CI 0.16-0.92).
In the United Kingdom Small Aneurysm Trial, the
hazard ratio (HR) for risk of rupture was four times higher
in women compared with men (HR 4.0, 95% CI 2.0-7.9; P
 .001), but the HR for the primary outcome of all-cause
mortality was worse for immediate repair in women (0.99)
than in men (0.80), although this did not achieve statistical
rysm related death (men 64 years old).1-4
neurysm related death stratified by age.1-4significance.43 Ruptured aneurysms seem also to occur at
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ter trial found that 53% (95% CI 47-60) of ruptured aneu-
rysms occurred in men younger than 80 years, and 72%
(95% CI 62-81) in females older than 80 years.5
Family history. The ADAM study found that a family
history positive for presence of AAA is associated with a
two-fold increase in the risk of having an AAA (OR 1.9;
95% CI 1.6-2.3) with no difference between men (OR
1.96, 95% CI 1.77-2.16) and women (OR 2.6, 95% CI
1.12-6.01).42 In the West Australia RCT a sister with an
AAA was associated with an OR of 2.7 (95% CI 1.4-5.3),44
and in a population study in Sweden, a first degree relative
with an AAA was associated with OR 4.4 (95% CI
1.5-13.0).45
Quality of life. Five trials used the SF-36 scale46-51
and one the General HealthQuestionnaire,48 and found no
difference between patients with AAA and those without,
participating in a screening program. The negative results
found in these studies are not surprising since the SF-36 is
not a good tool to measure anxiety (personal communica-
tion with D.L. Streiner, Feb 5, 2006). In addition, they did
not compare individuals entering a screening program vs
those who did not. One RCT, using a scale specifically
designed to assess changes in quality of life caused by
screening programs, found a significantly worse score in
individuals with AAA compared with those without.52 In-
vitation to screening is associated with anxiety in all partic-
ipants, which disappears with time.48
The cost of screening
The Viborg trial studied the cost effectiveness of the
screening program and estimated that the cost per life year
gained was €9057 (95% CI 5872-20,063 [C$12,736.29,
95% CI 8257-28,213, conversion rate €1 C$1.41]) after
5 years. The cost effectiveness improves over time with a
reduction in cost of 20% after 15 years (€1825, 95% CI
1185-4063, [C$2566, 95% CI 1666-5713]).53 Likewise,
the 7-year follow-up data for the MASS trial also found
AAA screening to be cost effective (£12,500 [95% CI
£8000-25,700] per life year gained).54
Using decision analysis, Wanhainen et al found that the
costs per life year gained ranged from US$8309 to
$14,084, according to the type of AAA screening strate-
gy,55 and Montreuil et al estimated a quality adjusted cost
utility ratio of C$6194 (95%CI 1892-10,837).56 Kim et al,
in a cost analysis of the MASS trial, demonstrated that the
societal cost of providing surgery for patients with AAA
increases by 47% if a screening program is implemented.57
This increased cost is due to the increased number of
elective procedures generated by the screening program,
which is not completely offset by the reduction in surgeries
done for ruptured AAA.57 The cost of screening increases if
compliance falls,58 perioperative mortality for urgent AAA
repair decreases, or perioperative mortality for elective AAA
repair increases.59 This is due to the relative decreases in the
number of lives saved in these scenarios.
Different imaging modalities have been investigated to
reduce the cost of screening programs. Lee et al studied theaccuracy of an ultrasound examination (USE) performed
by a vascular technician, who was instructed to examine the
aorta as fast as possible, to a maximum of 5 minutes (a
“quick scan”). When the two methods were compared
using decision analysis, the “quick scan” was associated
with a 39% cost saving per quality adjusted life year (QALY)
($11,215 with conventional ultrasound to $6850 with the
quick scan).60 In another study, a cohort of patients re-
ferred for assessment of vascular diseases at a tertiary center,
a portable ultrasound unit operated by a physician during
the physical examination was compared with a conventional
USE performed by technicians. The portable unit had a
sensitivity of 93% (95% CI 79-96), a specificity of 97% (95%
CI 93-99), a positive predictive value of 89% (95% CI
78-96), and a negative predictive value of 98% (95% CI
95-100).61 The current average cost of a focused aortic
USE in Canada (Table II, online only) is C$63 (SD 20);
the use of a “quick scan”, as described above, will reduce
this cost.
Using information from RCTs,1-4 a population based
study,9 and a metaanalysis,11 we projected the effect that a
screening program will have on the Canadian population.
Without a screening program, the aneurysm related mor-
tality over 41months is 5664 patients or 3283 patients if we
consider men65 years or men 65 to 75 years old, respec-
tively (Table III, online only). During the same period,
7014 or 4065 surgeries respectively, will be done following
the routine care of patients identified incidentally to have an
AAA or because of rupture. If a screening program is
implemented, the aneurysm related mortality over 41
months is 2094 for men65 years and 1214 for men 65 to
75 years old; the number of surgeries that would be per-
formed 15,158 and 8784, respectively (generated by
screening and, in nonparticipants, by AAA identified by
standard care or because of rupture) (Table IV, online
only). This translates to 3570 or 2069 lives saved (accord-
ing to the age group of individuals involved in the screening
program) over 41 months. This corresponds to an ARR of
30% and a NNT of 3. This means that we need to operate
on three AAA to save one life at an additional cost of
additional 8144 or 4719 surgeries, respectively.
We used the cost for elective and ruptured aneurysm
repair at the Hamilton Health Sciences (a tertiary vascular
university referral center) to generate an estimate of the
cost of treatment of AAAs (Table VIII, online only). We
estimate that the cost of treatment of AAAs in all men65
years old over a 41-month period, in the current system in
Canada is C$173,239,065 and if onlymen 65 to 75 years of
age are considered, the current costs are C$100,400,160.
If a screening program were implemented the cost would
be C$313,874,682 or C$181,883,889 for screening all
men 65 years of age or only men 65 to 75 years of age,
respectively.
Finally, the cost of repeated USE in patients with 3.4 to
4.4 cm AAA and in 4.5 to 5.4 cm AAA should be consid-
ered. Since AAAs grow at a rate of 2 mm per year,6-8 a base
case patient with a 3.5 cm AAA will require on average, 10
years of follow-up before the AAA becomes 5.5 cm and
JOURNAL OF VASCULAR SURGERY
Volume 45, Number 6 Mastracci et al 1271therefore considered for surgery. If an ultrasound per year is
done, the cost of 10 additional tests must be added.
STANDARD OF CARE OUTSIDE OF CANADA
The United States Preventative Services Task Force
(USPSTF) recommends one time screening for AAAs in
men 65 to 75 years of age who have ever smoked.62 The
Screening Abdominal Aortic Aneurysms Very Efficiently
(SAAAVE) Act was introduced into the Senate in 2005.63
This supports an AAA screening program that will start in
January 2007, and provide screening ultrasounds to male
ever-smokers when they turn 65 years old. The American
Society for Vascular Surgery (SVS) and the Society for
Vascular Medicine and Biology have a consensus statement
that adds women with cardiovascular risk factors (such as
smoking, hypertension, and peripheral vascular disease),
age 60 to 85 years and both men and women 50 years and
older with family history of aneurysm.31,42,64
The Vascular Society of Great Britain and Ireland has
organized a working group to examine the evidence exist-
ing for advocating population based screening, but no
screening guidelines have been suggested.65 There are
currently no formal guidelines or screening programs in
Australia and New Zealand (personal communication with
the President of the Australia and New Zealand Vascular
Society discussing their Society’s stance on AAA screen-
ing). In Sweden, programs for AAA screening are consid-
ered investigational until further evidence is available (per-
sonal communication from the President of the Swedish
Vascular Society discussing their Society’s stance on AAA
screening).66
DISCUSSION
The goal of screening programs is to use a diagnostic
test in apparently healthy individuals to identify those at risk
of morbidity and mortality from a disease.67 Individuals
at-risk will then be offered a treatment to divert the risk.
Screening programs are most effective in conditions which
are prevalent, have a detectable risk factor and for which a
safe and cost effective treatment exists.25 RCTs have shown
that AAA screening is effective in reducing AAA related
mortality in patients 65 to 80 years of age (RR 0.60; 95%CI
0.45-0.80). The benefit increases if only patients 65 to 75
years old are enrolled (RR 0.49; 95% CI 0.30-0.8). The
inclusion of older males reduces the benefit and cost effec-
tiveness of screening because of the shorter life expectancy
and higher perioperative mortality.41 Women have risk
factors for AAA similar to men and they appear to have a
greater risk of rupture. The benefit of screening in women,
however, is uncertain given the low prevalence of disease,
and that rupture occurs later in life and results of surgery
may be worse.
A screening program at a population level, and screen-
ing of a particular individual, are two related, but different
concepts. The former requires a careful examination of the
benefits at the population and the individual levels, and of
the societal cost. The latter requires an evaluation of the
constellation of risk factors which, in that particular indi-vidual, increases the probability of the presence of an aneu-
rysm.
The Geoffrey Rose “prevention paradox” applies to
mass screening programs, which may provide benefits to
the population at large, but provide minimal or no benefit
to the individual patient being screened.68 The individual
risk of participating in a screening program is an important
consideration when the intervention offered is associated
with 5.5% (95% CI 4-8)22 mortality and a 26% (95% CI
20-33) moderate to severe systemic complications.23 The
screening program will save the lives of those patients who
would have died because of rupture; however, it is also
associated with the perioperative mortality of elective sur-
gery (in our estimate of scenarios in the Canadian popula-
tion, 638 deaths if screening is applied to65 year, or 370
deaths if applied to 65- to 75-year-old men, respectively).
Although the population of patients who would have died
because of rupture and the population of patients who die
because of complications of elective surgery may somewhat
overlap, they are not necessarily the same. This means that
some people who may have never ruptured their AAA may
be killed by the screening program. Considering the indi-
vidual risk of a patient in the context of the available
evidence is crucial when determining the benefit of screen-
ing for AAA.
At a population level, our analysis of a screening pro-
gram of men65 or 65 to 75 years of age implemented in
the Canadian system, we have shown that it will reduce
aneurysm related mortality by 30%, corresponding to an
NNT of 3. This means that, to save one life, we will need to
screen 625 individuals and operate on three. Without a
screening program, patients would be generally operated
upon for AAA with a diameter of 5 to 5.5 cm according to
the results of RCTs and suggested guidelines.43,57,69 The
implementation of a screening program will increase the
number of surgeries, not only because of increased number
of AAAs identified by screening but also because a number
of individuals would be operated upon for AAAs of border-
line diameter, rapid change in size, patient preference,
patient and physician anxiety, or growth of the aneurysm
during follow-up. This effect is shown in Table IV where
the expected number of patients with AAA5.5 cm (8176
for males65 and 4739 for males 65 to 75) is smaller than
the actual number of individuals who will receive surgery
(13,355 for males 65 and 7740 for males 65 to 75). The
combination of these factors explains why the cost of
the screening program increases two-fold if implemented in
the male population 65 years ($140,635,617 vs
$81,483,727). An analysis of the risk reduction of the
available RCTs also suggests that the benefit of screening is
greater if only individuals 65 to 75 years are considered
(Fig 2).
RCTs have shown that in men 65 years of age, the
NNS to prevent one AAA related mortality is 769 (95% CI
1428-476).1-5 This is comparable to screening strategies of
fecal occult blood testing in colorectal cancer (NNS 808,
95% CI 563-1648) and mammography in breast cancer
(NNS  1887, 95% CI 1343-3505).70 A cost analysis of
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US$8309 to $14,084.55 This compares with colon cancer
screening (ie, fecal occult blood testing) that has a cost per
life year gained of US$10,000-US$25,00071 and with
breast cancer screening (ie, mammography), which has a
cost per life year gained of US$16 000 - US$20 000.72 The
interventions associated with these conditions, however,
have lower mortality and morbidity than open AAA repair.
In addition, these cost analysis studies were done in non-
Canadian health care system models. Over a 41-month
cycle (the average duration of the RCTs of screening pro-
grams), we estimated that the cost for treating of AAA in
Canada for people 65 to 75 years, in the current system, is
C$100,400,162. If a screening program were applied to
the same group of individuals, the cost would increase by
C$81,483,727 (Table VIII, online only). Considering that
the screening program will save 2069 patients (Table III
and Table IV, online only), the cost of treating AAA within
the screening program is C$39,383 per life gained. Our
review and meta-analysis of the literature shows that the
NNS for this age group is 625. At an average cost of C$60
for USE, this translates to an average screening cost per life
gained of C$37,500 over 41 months. The overall addi-
tional cost of the screening program is therefore
C$110,813 per life saved. Assuming that the average life
expectancy of patients undergoing AAA repair is 6 years,73
the cost per life year gained is C$18,469, which is in the
range of what is considered cost effective. This is in keeping
with similar studies of the effect of screening in a Canadian
setting.74
The majority of cost associated with AAA screening is
secondary to the additional elective surgeries produced by
the screening program. However, the number of ultra-
sounds performed adds to the cost of screening. There is
currently no evidence to guide the exact screening program
model that would be best applied to the Canadian Health
Care system, and further research will be needed to devise a
Canadian model that is both cost effective and efficient. For
example, in the four RCTs, ultrasounds were used to detect
patients with AAA 3 cm: the majority (74%, 95% CI
73-76) had small AAA (4.4 cm),2,3 which may never
reach the operative threshold during the patient’s life span,
and 11% (95% CI 10-13) had5 cm AAA in whom further
follow-up or surgery may be indicated to prevent rupture.
If screening were focused only on those patients at risk of a
large AAA (5 cm), the number of non useful USE could
be reduced with improved cost effectiveness. A focused
physical examination with a sensitivity for aneurysms 5
cm in diameter of 82% to 98%30,75 followed by an USE in
only those patients identified to have an AAA, may repre-
sent a strategy to reduce cost. This was supported by the
Canadian Task Force on Preventative Health.76 RCTs of
screening have not evaluated the use of physical exam
before USE for AAA screening. A review of the topic by
Frame et al77 suggests that the cost per life year for a
screening program is US$41,550 if USE alone is used and
US$28,741 if a preliminary physical examination is used to
screen those who are candidate for an US.Several factors influence the need and effectiveness of a
screening program for aneurysms. Decreasing the periop-
erative mortality of elective aneurysm repair will increase
the benefit of a screening program. Endovascular AAA
repair with an anticipated perioperative mortality of 1% to
2%23,24 offers promise as a better intervention, but further
studies of its impact on long-term costs and mortality are
necessary. Sensitivity analyses have shown that decreasing
the operative mortality of ruptured aneurysm repair de-
creases the cost effectiveness and benefit of a screening
program.59 It is therefore possible that if endovascular
technology are proven to improve the perioperative mor-
tality of ruptured AAA,78-90 the effectiveness of a screening
programwill require reassessment. Imposing a strategy that
subjects an asymptomatic population to a 5.5% risk of death
might not be justified if the perioperative mortality for
ruptured AAA were lower than the current 48%.
While the above arguments pertain to a population
based screening, an individual physician may elect to use
USE as a screening tool based on the anticipated individual
risk for AAA of a particular patient. A screening program at
a population level and screening of a particular individual
are related, but different concepts. The former requires a
careful examination of the benefits at the population and
the individual levels, and of the societal cost. The latter
requires an evaluation of the constellation of risk factors,
which in that particular individual, increases the probability
of the presence of an aneurysm. Age 70 years (OR 1.7),
family history (OR 1.9), smoking (OR 1.9), and cerebro-
vascular disease (OR 1.3) are powerful determinants of the
probability of having an AAA and are similar in men and
women.69 Since the odds ratio associated with these risk
factors are of similar magnitude, the effect of multiple risk
factors can be assumed to be additive. This means that in an
individual who is 70 years, with a positive family history,
a smoker and has cerebrovascular disease, we should antic-
ipate a six-fold increase in the risk of AAA. In this particular
individual, either man or woman, performing a USE is
justified and acceptable.
In conclusion, RCTs have shown benefit of implement-
ing a screening strategy at a population level in high risk
individuals. The cost effectiveness of these programs needs
to be carefully considered by governing health care agen-
cies and health care providers.
POSITION STATEMENT OF THE CANADIAN
SOCIETY FOR VASCULAR SURGERY FOR
SCREENING OF ABDOMINAL AORTIC
ANEURYSM
The Canadian Society for Vascular Surgery recom-
mends the following guidelines for screening patients for
AAA. This is based on a review of the evidence conducted in
2006. These guidelines should be revised as new evidence
becomes available through a systematic review commis-
sioned by the CSVS every 5 years. Levels of evidence are
based on the GRADE recommendations (Fig 3, Table V,
Table VI, Table VII, online only).91-93
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for men 65 to 75 years of age who are candidates for
surgery (anticipated low perioperative mortality and
morbidity) and are willing to participate.
● Evidence grade HIGH (RCT). Rationale: Relative risk
of AAA related mortality 0.49 (95% CI 0.3-0.8, P 
0.005) in screened men 65 to 75 years old compared
with nonscreened.1,2
2. Screening provides borderline to no benefit for men 75
to 80 years old.
● Evidence Grade HIGH (RCT). Rationale: Relative
risk of AAA related mortality 0.76 (95% CI 0.51-1.13,
P  0.17) in screened men 65 years old compared
with nonscreened.3,4
3. Population based screening of women 65 years old is
not recommended
● Evidence Grade HIGH (RCT). Rationale: Relative
Risk of AAA related mortality 1.49 (95% CI 0.72-
3.10) in screened women compared with non-
screened.5
4. Individualized investigation with USE of women 65
years old with multiple risk factors for AAA (smoking
history, cerebrovascular disease, family history of AAA)
may be beneficial.
● Evidence Grade MODERATE (Cohort data from
RCTs,44,69 population-based study).45 Rationale: In
women, these factors increase the risk of AAA one- to
seven-fold, but the baseline prevalence of4 cm AAA
is 0.1% (95% CI 0.03-0.3).
5. Ultrasound is an effective imaging modality for AAA
screening.
● Evidence Grade HIGH. (RCT Data,1-4 Cohort Stud-
ies 26-28). Rationale: All screening RCTs employ ultra-
sound in their screening strategy. Ultrasound has
100% sensitivity and 98% specificity.
6. In participants found by screening to have an aortic
diameter 3 cm, no follow-up ultrasound is necessary
before 3 to 5 years.
● Evidence Grade HIGH (Cohort study of RCTs1,4).
Rationale: A new AAA 3 cm was identified at 3- to
5-year follow-up, in 28% and 4.1% of patients with an
aortic diameter of 3 cm at the first ultrasound. All
new AAA were 4 cm.1,4
7. For individuals with aneurysms 3.0 to 4.4 cm, a yearly
abdominal ultrasound is an acceptable practice. The true
effective interval of re-screening is unknown for this
group and it is likely that every 2 years is also acceptable
for the smaller aneurysms.
● Evidence grade MODERATE (population based
study,6 cohort study of tertiary referral centers7). Ra-
tionale: Based on available evidence regarding growth
rates and risk of rupture: mean 0.21 cm growth rate for
aneurysms 3.0 to 4.4 cm SD 0.45 cm.
8. Screening individuals with popliteal artery aneurysms is
likely beneficial.
● Grade Low (Systematic Review94). Rationale: 37%
(95%CI 35-39) of patients with popliteal aneurysms inobservational studies have concurrent abdominal aor-
tic aneurysmal disease.
9. Screening men or women 65 years old is not likely to
be beneficial.
● Grade HIGH (RCT95 and Population based stud-
ies33). Rationale: The incidence of AAA in individuals
50 to 65 years of age is 0.9% (95% CI 0.8-1.0)95to
1.7% (95% CI 1.2-2.3).33
10. Screeningmen 65 to 75 years oldmay be cost effective.
● Evidence grade MODERATE (Cost analysis of RCT
data,57 a systematic review of studies of screening
costs55 and projections from real cost data at a Cana-
dian tertiary care center (unpublished data from Mc-
Master University). Rationale: The cost per life year
gained is estimated to be $12,813.
11. A strategy including physical examination and USE
needs to be investigated to screen AAA.
● Grade Low (Metaanalysis of cohort studies29,77 and
Cohort studies of tertiary referral center31,75). Ratio-
nale: Sensitivity 82% for AAA5 cm; cost of screening
program 30% lower.
12. The cost effectiveness of screening programs for AAA
should be re-evaluated if advances in vascular surgery
or endovascular techniques improve the mortality of
urgent or elective operative intervention for AAA.
● Grade HIGH (Decision analysis of RCT data96). Ra-
tionale: Cross tabulation of perioperative mortality for
ruptured and elective surgery for AAA using cost of the
screening program as dependent variable, demon-
strates that the cost improves if elective mortality is
reduced and ruptured mortality increases, and vice
versa.
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June 20071276.e2 Mastracci et alTable I. (Online only) Screening protocols of four RCTs of AAA screening.
1-year follow-up 3-month follow-up Referral to surgeon
MASS2 3-4.4 cm 4.4-5.4 cm 5.5 cm
Chichester4 3.0-4.4 cm 4.4-5.9 cm 6 cm
VIBORG1 3-5 cm 5 cm
3West Australia All results referred to family physician for standard managementTable II. (Online only) Cost of sonographic imaging of abdominal aorta
Jurisdiction
Cost† ultrasound examination
of abdominal aorta Source
United Kingdom £23.23 97
Sweden €42.78 98
Canada*
Ontario $ 53.80 Ontario Hospital Insurance Plan (OHIP) Website
Alberta $ 76.88 Alberta Ministry of Health Website
British Columbia $ 98.04 British Columbia Health Website
Manitoba $ 32.50 Manitoba Health Website
Newfoundland $ 54.19 Newfoundland Health
Prince Edward Island $ 42.72 PEI Health Website
Saskatchewan $ 85.50 Saskatchewan Health website.
$, Canadian Dollar.
*Includes physician and technical component, where available.
†If possible, fees for limited examinations of the abdominal aorta were recorded preferentially.Table III. (Online only) Anticipated aneurysm related mortality in the male population in Canada without a screening
program
Males 65 Males 65-75 Derivation
Population 1,834,100 1,063,017 Census 2005100
Individuals with AAA (3 cm) 110,046 63,781 6% total population1-4
Individuals with AAA (5 - 5.5 cm) 11,005 6378 0.6% total population1-4
Individuals who receive elective surgery by
standard care
4769 2764 0.26% of total population1-4
Individuals who will rupture over 41
months
6603 3827 0.36% total population1-4
Individuals with ruptured AAA who will die
before reaching the hospital or in hospital
without receiving surgery
4358 2526 66% individuals who will rupture over 41 months9
Individuals with ruptured AAA who will
undergo emergency surgery
2245 1301 34% individuals who will rupture over 41 months9
Perioperative mortality for individuals with
ruptured AAA
1078 625 48% individuals with ruptured AAA who will
undergo emergency surgery11
Perioperative mortality for individuals
undergoing elective repair
229 133 4.78% Individuals who receive elective surgery by
standard care1-4
Total mortality 5664 3283 Deaths from rupture AAA not undergoing surgery 
perioperative mortality of ruptured and elective
AAA repair over 41 months
The calculations are based on the natural history of the disease assuming that patients are left to standard care and for a 41-month follow-up (from randomized
1,3,51,99 9,11controlled trials of screening programs and population based studies ). Results are presented for the entire male population older than 65 and 65 to
75 years of age
JOURNAL OF VASCULAR SURGERY
Volume 45, Number 6 Mastracci et al 1276.e3Table IV. (Online only) Anticipated aneurysm related mortality in the male population in Canada with a screening
program in place
Males 65 Males 65-75 Derivation
Population eligible for screening 1,834,100 1,063,017 Census 2005100
Individuals expected to have 3 cm AAA 110,046 63,781 6% total population1-4
Individuals expected to have 5 - 5.5 cm
AAA
11,005 6378.0 0.6% total population1-4
Participating population
Population participating in screening
(compliers)
1,362,736 789,822 74.3% total population1-4
Number of individuals who will require at
least one USE required for screening*
1,362,736 789,822
Number of patients identified by USE with
3 cm AAA
81,764.2 47,389.3 6% of number of US1-4
Number of patients identified by USE with
5.5 cm AAA
8176 4739 0.6% number of US1-4
Individuals who receive elective surgery
because of screening
13,355 7740 0.98% number of US1-4
Perioperative mortality for individuals
undergoing elective repair
638 370 4.78% total number of elective surgery1-4
Nonparticipating population
Nonparticipating population 471,363 273,195 25.7% of total population1,3,51,99
Number of patients 3 cm AAA 28282 16392 6% noncomplier population1-4
Number of patients 5.5 cm AAA 2829 1639 0.6% noncomplier population1-4
Individuals who receive elective surgery by
standard care
1226 710 0.26% of nonparticipating population1-4
Individuals who will rupture over 41
months
1697 984 0.36% of nonparticipating Population1-4
Individuals with ruptured AAA who will die
before reaching the hospital or in hospital
without receiving surgery
1120 649 66% of nonparticipating who will rupture9
Individuals with ruptured AAA who will
undergo emergency surgery
577 334 34% of nonparticipating who will rupture9
Perioperative mortality for individuals with
ruptured AAA
277 161 48% of patients who will undergo emergency surgery11
Perioperative mortality for individuals
undergoing elective repair
59 34 4.78% total number of elective surgery1-4
Total mortality 1456 844 Death from RAAA before reaching hospital or in hospital
without receiving surgery  perioperative mortality
Total mortality of strategy 2094 1214
USE, ultrasound examination.
The calculations are based on the natural history of the disease assuming that patients are left to standard care and for a 41-month follow-up (from randomized
controlled trials of screening programs1,3,51,99and population based studies9,11). Results are presented for the entire male population older than 65 and 65 to
75 years of age. Data are given for the proportion of the same population, which will not participate in the screening program. In the latter we assume that the
risk of rupture is similar to the one of those participating in the screening program.
*In a 41-month screening cycle patients invited to the screening program may require multiple USE (Table I).Table V. (Online only) Quality of evidence of randomized controlled trials of AAA screening101
Trial Allocation concealment Randomization
Outcome assessors
blinded
Intention to treat
analysis
Protocolized
follow-up Grade 91-93
Viborg1,96 No No Yes Yes Yes High
MASS2 No Yes No Yes Yes High
West Australia3 No No Yes Yes No High
Chichester 4,5 No Yes No Yes Yes High
ADAM 69 Yes Yes Yes Yes Yes High
22UKSAT Yes Yes No Yes Yes High
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Author
Search
strategy
reported
Type of studies
included
More than one
database
searched
Data extraction
done in
duplicate
Assessment of
study quality
included
Funnel Plot
or measure
of
publication
bias
Description
of the
population
Precision of
estimate of
effect Grade91-93
Lederle FA29 Yes Nonrandomized
studies
No No Yes No Yes Moderate Moderate
Dawson I94 No Case series and
retrospective
hospital based
ND ND No No Yes High High
Frame PS77 No Nonrandomized
studies
No ND No No Yes Moderate ModerateND, not described.Table VII. (Online only) Quality of evidence for observational AAA screening studies103
Author Study design
Multicenter
trial
Details of coding
and classifying
data
Outcome Assessors
Blinded
Size of the
estimate
Precision of
the
estimate Grade91-93
Singh K 26 Population
based
No NA NA NA High Moderate
Bengtsson H9 Population
based
Yes Yes NA Large High High
Reed WW6 Population
based
No Yes NA NA Moderate Moderate
Tayal VS27 Prospective
non-
randomized
No NA NA Large High Moderate
Pleumeekers HJCM28 Population
based
No NA Yes Large High Moderate
Bernstein EF7 Population
based
No No No NA Moderate Low
Morris GE33 Population
based
No NA No NA High Low
Fink HA31 Cohort
study
No NA Yes Large High Moderate
Venkatasubramaniam AK75 Cohort
study
No NA Yes Large High ModerateNA, not applicable.
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program in place
Current status Screening program
65 yrs 65 – 75 65 yrs 65 – 75
Individuals who receive elective surgery by standard care 4769 2764 1226 710
Cost $96,181,192 $55,744,352 $24,725,968 $14,319,280
Individuals with RAAA who will undergo emergency surgery 2245 1301 577 334
Cost $77,057,873 $44,655,810 $19,805,075 $11,464,289
Individuals who receive elective surgery because of screening -- -- 13355 7740
Cost -- -- $269,343,640 $156,100,320
Total Operative Costs $173,239,065 $100,400,162 $313,874,682 $181,883,889
The methodology of this cost analysis is as follows: Costing data was collected at the level of each functional center, with breakdowns for staffing, drugs, and
other supplies and expenses. Nursing costs for the ICU and vascular ward were derived on the basis of an average hour per patient day value, based on recorded
work load. Laboratory and diagnostic imaging costs were averaged across the entire cohort of patients treated for elective and ruptured abdominal aortic
aneurysms. Finally, an indirect (overhead) cost allocation was made at a rate of 23%. Costing for allied health care was not considered.
The calculations are based on the natural history of the disease assuming that patients are left to standard care and for a 41-month follow-up (from randomized
controlled trials of screening programs1,3,51,99 and population based studies9,11 see tables 3 and 4). Projections for the current systems are for the entire male
population older than 65 years of age. Projections in the screening group are presented for the entire male population older than 65 and 65 to 75 years of age.
Calculations are based on data from a costing study at a Canadian tertiary care center, which found the average cost of conventional open repair of AAA is
$20,168.00, and the average cost of a repair for ruptured AAA is $34, 324.22.
